TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 1.30nMAssay Description:For the assay, 11 different concentrations in the range from 20 μM to 0.073 nM were prepared from a 2 mM DMSO solution of the test substance. 50...More data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 1.30nMAssay Description:For the assay, 11 different concentrations in the range from 20 μM to 0.073 nM were prepared from a 2 mM DMSO solution of the test substance. 50...More data for this Ligand-Target Pair
Affinity DataIC50: 2.80nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the presence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency...More data for this Ligand-Target Pair
Affinity DataIC50: 3.20nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
Affinity DataIC50: 3.30nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
Affinity DataIC50: 3.40nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
Affinity DataIC50: 3.40nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 3.40nMAssay Description:For the assay, 11 different concentrations in the range from 20 μM to 0.073 nM were prepared from a 2 mM DMSO solution of the test substance. 50...More data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 3.40nMAssay Description:For the assay, 11 different concentrations in the range from 20 μM to 0.073 nM were prepared from a 2 mM DMSO solution of the test substance. 50...More data for this Ligand-Target Pair
Affinity DataIC50: 3.5nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 3.70nMAssay Description:For the assay, 11 different concentrations in the range from 20 μM to 0.073 nM were prepared from a 2 mM DMSO solution of the test substance. 50...More data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 3.70nMAssay Description:For the assay, 11 different concentrations in the range from 20 μM to 0.073 nM were prepared from a 2 mM DMSO solution of the test substance. 50...More data for this Ligand-Target Pair
Affinity DataIC50: 3.70nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
Affinity DataIC50: 3.70nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the presence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency...More data for this Ligand-Target Pair
Affinity DataIC50: 4.10nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the presence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency...More data for this Ligand-Target Pair
Affinity DataIC50: 5.5nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the presence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency...More data for this Ligand-Target Pair
Affinity DataIC50: 5.60nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the presence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency...More data for this Ligand-Target Pair
Affinity DataIC50: 5.90nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the presence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency...More data for this Ligand-Target Pair
Affinity DataIC50: 6nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
Affinity DataIC50: 6.10nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the presence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency...More data for this Ligand-Target Pair
Affinity DataIC50: 6.30nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
Affinity DataIC50: 6.5nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
Affinity DataIC50: 7nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 7.20nMAssay Description:For the assay, 11 different concentrations in the range from 20 μM to 0.073 nM were prepared from a 2 mM DMSO solution of the test substance. 50...More data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 7.20nMAssay Description:For the assay, 11 different concentrations in the range from 20 μM to 0.073 nM were prepared from a 2 mM DMSO solution of the test substance. 50...More data for this Ligand-Target Pair
Affinity DataIC50: 7.60nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the presence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency...More data for this Ligand-Target Pair
Affinity DataIC50: 8.10nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
Affinity DataIC50: 8.10nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
Affinity DataIC50: 8.40nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
Affinity DataIC50: 8.70nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
Affinity DataIC50: 8.80nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
Affinity DataIC50: 8.90nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 8.90nMAssay Description:For the assay, 11 different concentrations in the range from 20 μM to 0.073 nM were prepared from a 2 mM DMSO solution of the test substance. 50...More data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 8.90nMAssay Description:For the assay, 11 different concentrations in the range from 20 μM to 0.073 nM were prepared from a 2 mM DMSO solution of the test substance. 50...More data for this Ligand-Target Pair
Affinity DataIC50: 10nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the presence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency...More data for this Ligand-Target Pair
Affinity DataIC50: 10nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 10.7nMAssay Description:For the assay, 11 different concentrations in the range from 20 μM to 0.073 nM were prepared from a 2 mM DMSO solution of the test substance. 50...More data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 10.7nMAssay Description:For the assay, 11 different concentrations in the range from 20 μM to 0.073 nM were prepared from a 2 mM DMSO solution of the test substance. 50...More data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 10.8nMAssay Description:For the assay, 11 different concentrations in the range from 20 μM to 0.073 nM were prepared from a 2 mM DMSO solution of the test substance. 50...More data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 10.8nMAssay Description:For the assay, 11 different concentrations in the range from 20 μM to 0.073 nM were prepared from a 2 mM DMSO solution of the test substance. 50...More data for this Ligand-Target Pair
Affinity DataIC50: 11nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
Affinity DataIC50: 11nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the presence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency...More data for this Ligand-Target Pair
Affinity DataIC50: 11nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
Affinity DataIC50: 11nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
Affinity DataIC50: 12nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the presence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency...More data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 12.3nMAssay Description:For the assay, 11 different concentrations in the range from 20 μM to 0.073 nM were prepared from a 2 mM DMSO solution of the test substance. 50...More data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 12.3nMAssay Description:For the assay, 11 different concentrations in the range from 20 μM to 0.073 nM were prepared from a 2 mM DMSO solution of the test substance. 50...More data for this Ligand-Target Pair
Affinity DataIC50: 13nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the absence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency ...More data for this Ligand-Target Pair
Affinity DataIC50: 13nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the presence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency...More data for this Ligand-Target Pair
Affinity DataIC50: 13nMAssay Description:Notably, Compound Examples are tested in the FLIPR assays in the presence (hB1 free IC50) of 0.1% BSA in assay buffer, in order to assess the potency...More data for this Ligand-Target Pair